Cytokinetics’ Failure In ALS Clears Way For Focus On Aficamten
Executive Summary
With a data monitoring committee finding no signs of efficacy in a Phase III trial of ALS candidate reldesemtiv, Cytokinetics can conserve cash and center on aficamten for hypertrophic cardiomyopathy.
You may also be interested in...
Apellis Follows Wave Life By Shelving ALS Candidate After Trial Miss
Apellis’s pegcetacoplan – approved for two other indications – will not go forward in amyotrophic lateral sclerosis after a Phase II failure, two days after Wave Life made a similar call in the neurodegenerative disease.
BMS Advances Cardiovascular Growth Plans With Milvexian, Camzyos Milestones
Bristol and Janssen detailed the now under way Phase III program for Factor XIa inhibitor milvexian and BMS shared data at ACC to help prescribers get comfortable with Camzyos, launched last year.
Cytokinetics To Move On From Omecamtiv After FDA’s Complete Response Letter
Company said it will not conduct the additional Phase III trial recommended by the US FDA. Instead, it will focus on its cardiac myosin inhibitor, aficamten, and look for partners to take omecamtiv forward.